Search Results - "Mathôt, R. A. A."

Refine Results
  1. 1

    Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications by Hazendonk, H. C. A. M., Lock, J., Mathôt, R. A. A., Meijer, K., Peters, M., Laros‐van Gorkom, B. A. P., Meer, F. J. M., Driessens, M. H. E., Leebeek, F. W. G., Fijnvandraat, K., Cnossen, M. H.

    Published in Journal of thrombosis and haemostasis (01-03-2016)
    “…Essentials Targeting of factor VIII values is a challenge during perioperative replacement therapy in hemophilia. This study aims to identify the extent and…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol by Franken, L G, de Winter, B C M, van Esch, H J, van Zuylen, L, Baar, F P M, Tibboel, D, Mathôt, R A A, van Gelder, T, Koch, B C P

    “…A variety of medications are used for symptom control in palliative care, such as morphine, midazolam and haloperidol. The pharmacokinetics of these drugs may…”
    Get more information
    Journal Article
  4. 4
  5. 5

    Are higher antidepressant plasma concentrations associated with fall risk in older antidepressant users? by Pronk, A. C., van Poelgeest, E. P., Seppala, L. J., Ploegmakers, K. J., Stricker, B. H., Swart, K. M. A., van Dijk, S. C., Oliai Araghi, S., de Groot, L. C. P. G. M., van Schoor, N. M., Mathôt, R. A. A., van der Velde, N.

    Published in European geriatric medicine (01-02-2023)
    “…Key summary points Aim To explore the association between antidepressant plasma concentrations and fall risk in older users. Findings An association was found…”
    Get full text
    Journal Article
  6. 6

    The role of plasma concentrations and drug characteristics of beta‐blockers in fall risk of older persons by Ploegmakers, K. J., Poelgeest, E. P., Seppala, L. J., Dijk, S. C., Groot, L. C. P. G. M., Oliai Araghi, S., Schoor, N. M., Stricker, B., Swart, K. M. A., Uitterlinden, A. G., Mathôt, R. A. A., Velde, N.

    Published in Pharmacology research & perspectives (01-12-2023)
    “…Beta‐blocker usage is inconsistently associated with increased fall risk in the literature. However, due to age‐related changes and interindividual…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Determinants of drug absorption in different ECMO circuits by Wildschut, E. D., Ahsman, M. J., Allegaert, K., Mathot, R. A. A., Tibboel, D.

    Published in Intensive care medicine (01-12-2010)
    “…Purpose The aim of this in vitro study was to evaluate potential determinants of drug loss in different ECMO circuits. Methods Midazolam, morphine, fentanyl,…”
    Get full text
    Journal Article
  9. 9

    Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play? by Hazendonk, H.C.A.M., van Moort, I., Mathôt, R.A.A., Fijnvandraat, K., Leebeek, F.W.G., Collins, P.W., Cnossen, M.H.

    Published in Blood reviews (01-07-2018)
    “…Replacement therapy with clotting factor concentrates (CFC) is the mainstay of treatment in hemophilia. Its widespread application has led to a dramatic…”
    Get full text
    Journal Article
  10. 10

    Yondelis® (trabectedin, ET-743): the development of an anticancer agent of marine origin by van Kesteren, Ch, de Vooght, M. M. M, López-Lázaro, L, Mathôt, R. A. A, Schellens, J. H. M, Jimeno, J. M, Beijnen, J. H

    Published in Anti-cancer drugs (01-08-2003)
    “…Yondelis (trabectedin, ET-743) is a novel antitumor agent derived from a marine source, the Caribbean tunicate Ecteinascidia turbinata. Preclinical studies…”
    Get full text
    Journal Article
  11. 11

    In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients by Preijers, T., van Spengler, M. W. F., Meijer, K., Fijnvandraat, K., Fischer, K., Leebeek, F. W. G., Cnossen, M. H., Mathôt, R. A. A.

    Published in European journal of clinical pharmacology (01-02-2022)
    “…Purpose Hemophilia B is a bleeding disorder, caused by a factor IX (FIX) deficiency. Recently, FIX concentrates with extended half-life (EHL) have become…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Population Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Prophylaxis in Pediatric Acute Lymphoblastic Leukemia Patients by Sassen, S D T, Mathôt, R A A, Pieters, R, de Haas, V, Kaspers, G J L, van den Bos, C, Tissing, W J E, te Loo, D M W W, Bierings, M B, van Westreenen, M, van der Sluis, I M, Zwaan, C M

    Published in Clinical infectious diseases (05-11-2020)
    “…Abstract Background Ciprofloxacin is used as antimicrobial prophylaxis in pediatric acute lymphoblastic leukemia (ALL) to decrease infections with…”
    Get full text
    Journal Article
  14. 14

    In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients by Preijers, T., Hazendonk, H. C. A. M., Fijnvandraat, K., Leebeek, F. W. G., Cnossen, M. H., Mathôt, R. A. A.

    Published in Journal of thrombosis and haemostasis (01-09-2017)
    “…Essentials Individual pharmacokinetic (PK) parameters can be obtained by limited sampling strategies (LSSs). Following 100 IU kg−1 rFIX, LSSs with 1 to 3…”
    Get full text
    Journal Article
  15. 15

    Fasting-Induced Changes in Hepatic P450 Mediated Drug Metabolism Are Largely Independent of the Constitutive Androstane Receptor CAR by de Vries, E M, Lammers, L A, Achterbergh, R, Klümpen, H-J, Mathot, R A A, Boelen, A, Romijn, J A

    Published in PloS one (19-07-2016)
    “…Hepatic drug metabolism by cytochrome P450 enzymes is altered by the nutritional status of patients. The expression of P450 enzymes is partly regulated by the…”
    Get full text
    Journal Article
  16. 16

    Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer by Kruijtzer, C. M. F., Boot, H., Beijnen, J. H., Lochs, H. L., Parnis, F. X., Planting, A. S. T., Pelgrims, J. M. G., Williams, R., Mathôt, R. A. A., Rosing, H., Schot, M. E., van Tinteren, H., Schellens, J. H. M.

    Published in Annals of oncology (01-02-2003)
    “…Background: Pharmacokinetic study has shown that co-administration of cyclosporin A (CsA), which acts as a P-glycoprotein (P-gp) and CYP-3A blocker, resulted…”
    Get full text
    Journal Article
  17. 17

    Effects of nutritional status on acetaminophen measurement and exposure by Achterbergh, R., Lammers, L. A., Kuijsten, L., Klümpen, H. J., Mathôt, R. A. A., Romijn, J. A.

    Published in Clinical toxicology (Philadelphia, Pa.) (02-01-2019)
    “…Introduction: Fasting, as well as a high-fat diet, might increase the risk on acetaminophen-induced toxicity after an acute overdose. Therefore, it has been…”
    Get full text
    Journal Article
  18. 18

    A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism by Hunfeld, N. G., Touw, D. J., Mathot, R. A., van Schaik, R. H., Kuipers, E. J.

    Published in Alimentary pharmacology & therapeutics (01-04-2012)
    “…Summary Background Esomeprazole and rabeprazole are metabolised in the liver by means of the CYP2C19 enzyme, which has several functional genetic…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Feasibility of sedation and analgesia interruption following cannulation in neonates on extracorporeal membrane oxygenation by Wildschut, E. D., Hanekamp, M. N., Vet, N. J., Houmes, R. J., Ahsman, M. J., Mathot, R. A. A., de Wildt, S. N., Tibboel, D.

    Published in Intensive care medicine (01-09-2010)
    “…Purpose In most extracorporeal membrane oxygenation (ECMO) centers patients are heavily sedated to prevent accidental decannulation and bleeding complications…”
    Get full text
    Journal Article